Atovaquone Targets STAT3 in Ovarian Cancer Spheroids by Neil, Kayli E
University of New Hampshire 
University of New Hampshire Scholars' Repository 
Honors Theses and Capstones Student Scholarship 
Spring 2020 
Atovaquone Targets STAT3 in Ovarian Cancer Spheroids 
Kayli E. Neil 
University of New Hampshire, Durham 
Follow this and additional works at: https://scholars.unh.edu/honors 
Recommended Citation 
Neil, Kayli E., "Atovaquone Targets STAT3 in Ovarian Cancer Spheroids" (2020). Honors Theses and 
Capstones. 503. 
https://scholars.unh.edu/honors/503 
This Senior Honors Thesis is brought to you for free and open access by the Student Scholarship at University of 
New Hampshire Scholars' Repository. It has been accepted for inclusion in Honors Theses and Capstones by an 
authorized administrator of University of New Hampshire Scholars' Repository. For more information, please 
contact nicole.hentz@unh.edu. 
      Atovaquone Targets STAT3 in Ovarian Cancer Spheroids 
 
Senior Honors Thesis 
Kayli Neil and Sarah Walker 
May 2020 
 
University of New Hampshire, Durham, NH 
College of Life Sciences and Agriculture 
Department of Molecular, Cellular, and Biomedical Sciences 
 
Walker Lab, Rudman Hall, Room 152 
46 College Road, Durham, NH 03824 
 
Contact: kneil9716@gmail.com or ken1009@wildcats.unh.edu  
 
ABSTRACT 
      Ovarian cancer remains a deadly disease for countless women. Recent evidence demonstrates 
that ovarian cancer cell clusters, spheroids, are important in promoting ovarian recurrence and 
metastasis.  Often these spheroids are resistant to therapy. Therefore, we were interested in 
identifying drugs that could target ovarian cancer spheroids. Analysis of gene expression 
identified the STAT3 signaling pathway as a pathway enriched in 3D growing ovarian cancer 
cells. STAT3 is a transcription factor that is activated by tyrosine phosphorylation in about 70% 
of high grade serous ovarian cancers. Using shRNA targeting STAT3 and the upstream signaling 
molecule, GP130, we found that reduction of both STAT3 and its upstream signaling molecule 
GP130 reduced the growth of spheroids. This suggested that targeting STAT3 or an upstream 
signaling molecule might be a viable treatment option. Atovaquone, used normally for the 
treatment of malaria or the prevention of pneumocystic pneumonia, inhibits STAT3 activation by 
inhibiting the expression of GP130 on the cell surface. Therefore, showing that atovaquone has 
potential in decreasing viability in ovarian cancer cells. 
 
 
